NCT03617679 2026-02-23
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
University of Colorado, Denver
Phase 2 Active not recruiting
Clinical Trials
69 trialsNCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03671811 2026-01-06
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
City of Hope Medical Center
Phase 2 Active not recruiting
NCT01068249 2025-11-18
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT05036681 2025-09-17
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00924027 2025-09-05
A Study of Patients Receiving High-Dose Rate Brachytherapy
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03300557 2025-08-29
Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03395080 2025-08-01
P204
Leap Therapeutics, Inc.
Phase 2 Completed
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT02899793 2025-06-11
Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
Yale University
Phase 2 Completed
NCT03694262 2025-05-30
EndoBARR
Medical College of Wisconsin
Phase 2 Active not recruiting
NCT03835819 2025-05-15
A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT00513786 2025-03-28
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT04750941 2025-03-04
Study of Copanlisib and Ketogenic Diet
Columbia University
Phase 2 Terminated
NCT03241745 2024-12-27
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02035787 2024-12-18
Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT02431676 2024-08-28
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT04205630 2024-05-30
SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma
Byondis B.V.
Phase 2 Completed
NCT04743999 2024-03-29
Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
Henry Ford Health System
Phase 2 Terminated
NCT03189446 2024-03-08
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
University of Oklahoma
Phase 2 Completed
NCT03476798 2024-02-15
Clovis-001
University of Oklahoma
Phase 2 Completed
NCT03015129 2024-02-06
A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04511026 2023-10-11
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
Stanford University
Phase 2 Terminated
NCT04171700 2023-10-02
LODESTAR
pharmaand GmbH
Phase 2 Terminated
NCT01111461 2023-06-22
Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression
Eisai Inc.
Phase 2 Completed
NCT01367002 2023-05-17
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
Yale University
Phase 2 Completed
NCT03642990 2023-04-12
NR in Chemo-induced Peripheral Neuropathy
University of Iowa
Phase 2 Terminated
NCT02549989 2023-02-22
Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT02025985 2023-01-26
SIGN
Karyopharm Therapeutics Inc
Phase 2 Completed
NCT03394027 2022-08-23
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03077698 2022-06-07
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Xenetic Biosciences, Inc.
Phase 2 Terminated
NCT02549209 2022-03-02
Pembro/Carbo/Taxol in Endometrial Cancer
Big Ten Cancer Research Consortium
Phase 2 Completed
NCT02725268 2021-11-24
A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer
Takeda
Phase 2 Completed
NCT03245736 2021-11-04
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
Seagen Inc.
Phase 2 Completed
NCT00900562 2021-10-28
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
PharmaMar
Phase 2 Terminated
NCT00542490 2020-08-21
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Patients With Endometrioid Cancer
University of Oklahoma
Phase 2 Completed
NCT00319748 2019-08-26
Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00095979 2019-07-24
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00096447 2019-07-24
Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00462826 2019-07-23
VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00723255 2019-07-23
Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00729586 2019-07-23
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT01717391 2019-03-26
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
University of Iowa
Phase 2 Completed
NCT00331760 2019-02-26
Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00910091 2019-01-30
The Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer
Ipsen
Phase 2 Completed
NCT01251354 2019-01-14
Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy
Ipsen
Phase 2 Terminated
NCT01420081 2019-01-08
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
Phase 2 Terminated
NCT00483327 2018-04-04
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
NYU Langone Health
Phase 2 Completed